Pipeline
SCAI-001
Dry Eye Syndrome
SCAI-001
SCAI-001
Cyclosporine A
Cyclosporine A is a widely used medication to treat dry eye syndrome to date. Due to its poor aqueous solubility, however, commercial
formulations in the current market inevitably contain a considerable amount of surfactants and/or oils, which often cause burning sensation,
irritation or pains in the eye. In contrast, our proprietary formulation of cyclosporine A contains significantly reduced amount of surfactants or oils,
yet delivering efficacies equal to or better than commercial products in multitude of sign and symptom end points.
SCAI-003
Wet AMD
SCAI-003
SCAI-003
Sunitinib
Wet age-related macular degeneration (wet AMD) is a disastrous disease of vision impairment in the macular region of the retina due to abnormal
blood vessel formation, leading to blindness in severe cases. The only medicinal treatment currently used for wet AMD is an intravitreal injection
of anti-VEGF such as ranibizumab and aflibercept, which often accompanies various adverse effects: endophthalmitis, intraocular inflammation, and subconjunctival/subretinal hemorrhage. Preparation of an effective eyedrop for wet AMD is regarded as the Holy Grail of the research to date. In order to provide a safer treatment to wet AMD patients, we developed eye-drop formulations of VEGFR tyrosine kinase inhibitors, sunitinib (SCAI-003), pazopanib (SCAI-004), and axitinib (SCAI-005) dispersions. Given our proprietary technology to efficiently deliver drugs across the cornea to the retina, the eye-drop formulations will provide an effective, non-invasive solution for wet AMD patients.
SCAI-101
Nonsurgical Fat Reduction
SCAI-101
SCAI-101
Deoxycholic Acid
Deoxycholic acid is a key component of submental fat removal injection, currently used under the trade name Kybella. SCAI has prepared an
aqueous dispersion of its sodium salt form, sodium deoxycholate, as a cream formulation for topical application. With the nonsurgical method in
hand, it is anticipated that a much less painful option of submental fat removal is feasible over the current injection.
SCAI-502
COVID-19
SCAI-502
SCAI-502
Niclosamide
Niclosamide has been used as a traditional anthelminthic drug since the mid-20th century, which is once again under the spotlight based on its
micromolar potency against SARS-CoV-2 amid the worldwide pandemic. However, due to its poor solubility in water, there is a limitation of it
being orally administered with a high bioavailability. Nonetheless, our proprietary technology enables a drastic improvement of its oral
bioavailability which has been demonstrated in a rat model. Efficacy and toxicity studies are currently underway.